Exagen Inc. has reached a major milestone by completing its 1,000,000th AVISE CTD test, a diagnostic tool for autoimmune and connective tissue diseases. This achievement highlights the company’s ...

CARLSBAD, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the completion of its 1,000,000 th AVISE CTD test, marking a significant ...

What is the AVISE® CTD? AVISE® CTD is a blood test that can help doctors diagnose lupus and other autoimmune diseases — like rheumatoid arthritis, Sjögren's syndrome, or scleroderma. The test may be ...

Exagen (XGN) announced the completion of its 1,000,000th AVISE CTD test, marking a significant milestone that underscores the company’s dedication to supporting patients and clinicians managing ...

CEO John Aballi highlighted several important developments, including the successful integration of new biomarkers into the AVISE CTD test. He noted that these biomarkers have driven a $90 incremental ...

We also saw the testing volumes for AVISE CTD, including AVISE Lupus, set new records. In the second quarter, the test grew approximately 6% year over year and 13% quarter over quarter to a record ...

- Revenue (GAAP) rose to $17.2 million, surpassing analyst expectations by 5.5% and grew 14.2% year over year. - AVISE CTD test volume increased 14% sequentially, and the trailing-twelve-month average ...

John Aballi, CEO, stated that "Q2 revenue came in at $17.2 million, representing 14% year-over-year growth and the highest quarterly revenue in company history." He highlighted substantial AVISE CTD ...